哌拉西林-他唑巴坦对比头孢西丁作为胰十二指肠切除术抗菌预防的随机临床试验
该实用、开放标签、多中心、随机3期临床试验在美加26家医院纳入778例开放胰十二指肠切除术成人患者,比较哌拉西林-他唑巴坦与头孢西丁围手术期预防对术后30天手术部位感染的影响。结果显示哌拉西林-他唑巴坦组30天手术部位感染率低于头孢西丁组(19.8% vs 32.8%),且术后脓毒症和临床相关术后胰瘘发生率更低。
要点
- 开放胰十二指肠切除术围手术期预防使用哌拉西林-他唑巴坦较头孢西丁降低30天手术部位感染率(19.8% vs 32.8%)。
- 哌拉西林-他唑巴坦组术后脓毒症(4.2% vs 7.5%)和临床相关术后胰瘘(12.7% vs 19.0%)发生率低于头孢西丁组。
- 30天死亡率两组分别为1.3%(5/378)和2.5%(10/400),差异无统计学显著(P = .32)。
核心结论
- 在开放胰十二指肠切除术患者中,围手术期预防使用哌拉西林-他唑巴坦降低了术后手术部位感染、胰瘘及手术部位感染的多个下游后遗症。
- 研究结果支持将哌拉西林-他唑巴坦作为开放胰十二指肠切除术的标准治疗。
研究设计与样本
- 实用、开放标签、多中心、随机3期临床试验,在美国和加拿大26家医院开展。
- 2017年11月至2021年8月入组,随访至2021年12月。
- 纳入因任何指征接受开放胰十二指肠切除术的成人;排除对研究药物过敏、活动性感染、长期使用类固醇、显著肾功能不全、妊娠或哺乳者。
- 采用1:1区组随机,按术前胆道支架存在与否分层;参与者、研究者和统计分析人员对治疗分配均非盲。
- 共778例参与者:哌拉西林-他唑巴坦组378例(中位年龄66.8岁;男性233例,占61.6%),头孢西丁组400例(中位年龄68.0岁;男性223例,占55.8%)。
主要发现
- 30天手术部位感染率哌拉西林-他唑巴坦组为19.8%,头孢西丁组为32.8%;绝对差为-13.0%(95% CI,-19.1%至-6.9%),P < .001。
- 术后脓毒症发生率哌拉西林-他唑巴坦组为4.2%,头孢西丁组为7.5%;差值为-3.3%(95% CI,-6.6%至0.0%),P = .02。
- 临床相关术后胰瘘发生率哌拉西林-他唑巴坦组为12.7%,头孢西丁组为19.0%;差值为-6.3%(95% CI,-11.4%至-1.2%),P = .03。
- 30天死亡率哌拉西林-他唑巴坦组为1.3%(5/378),头孢西丁组为2.5%(10/400);差值为-1.2%(95% CI,-3.1%至0.7%),P = .32。
- 试验基于预设停止规则在中期分析时终止。
关键数值与推荐
- 干预组:哌拉西林-他唑巴坦(3.375 g或4 g静脉给药)作为围手术期抗菌预防。
- 对照组:头孢西丁(2 g静脉给药)作为标准治疗。
- 主要结局:术后30天内发生手术部位感染。
- 次要终点:30天死亡率、临床相关术后胰瘘和脓毒症。
- 所有数据作为美国外科医师学会国家外科质量改进计划的一部分收集。
临床怎么用
- 研究结果支持将哌拉西林-他唑巴坦作为开放胰十二指肠切除术的标准治疗。
- 原文未报告其他临床应用推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite improvements in perioperative mortality, the incidence of postoperative surgical site infection (SSI) remains high after pancreatoduodenectomy. The effect of broad-spectrum antimicrobial surgical prophylaxis in reducing SSI is poorly understood. OBJECTIVE: To define the effect of broad-spectrum perioperative antimicrobial prophylaxis on postoperative SSI incidence compared with standard care antibiotics. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, open-label, multicenter, randomized phase 3 clinical trial at 26 hospitals across the US and Canada. Participants were enrolled between November 2017 and August 2021, with follow-up through December 2021. Adults undergoing open pancreatoduodenectomy for any indication were eligible. Individuals were excluded if they had allergies to study medications, active infections, chronic steroid use, significant kidney dysfunction, or were pregnant or breastfeeding. Participants were block randomized in a 1:1 ratio and stratified by the presence of a preoperative biliary stent. Participants, investigators, and statisticians analyzing trial data were unblinded to treatment assignment. INTERVENTION: The intervention group received piperacillin-tazobactam (3.375 or 4 g intravenously) as perioperative antimicrobial prophylaxis, while the control group received cefoxitin (2 g intravenously; standard care). MAIN OUTCOMES AND MEASURES: The primary outcome was development of postoperative SSI within 30 days. Secondary end points included 30-day mortality, development of clinically relevant postoperative pancreatic fistula, and sepsis. All data were collected as part of the American College of Surgeons National Surgical Quality Improvement Program. RESULTS: The trial was terminated at an interim analysis on the basis of a predefined stopping rule. Of 778 participants (378 in the piperacillin-tazobactam group [median age, 66.8 y; 233 {61.6%} men] and 400 in the cefoxitin group [median age, 68.0 y; 223 {55.8%} men]), the percentage with SSI at 30 days was lower in the perioperative piperacillin-tazobactam vs cefoxitin group (19.8% vs 32.8%; absolute difference, -13.0% [95% CI, -19.1% to -6.9%]; P < .001). Participants treated with piperacillin-tazobactam, vs cefoxitin, had lower rates of postoperative sepsis (4.2% vs 7.5%; difference, -3.3% [95% CI, -6.6% to 0.0%]; P = .02) and clinically relevant postoperative pancreatic fistula (12.7% vs 19.0%; difference, -6.3% [95% CI, -11.4% to -1.2%]; P = .03). Mortality rates at 30 days were 1.3% (5/378) among participants treated with piperacillin-tazobactam and 2.5% (10/400) among those receiving cefoxitin (difference, -1.2% [95% CI, -3.1% to 0.7%]; P = .32). CONCLUSIONS AND RELEVANCE: In participants undergoing open pancreatoduodenectomy, use of piperacillin-tazobactam as perioperative prophylaxis reduced postoperative SSI, pancreatic fistula, and multiple downstream sequelae of SSI. The findings support the use of piperacillin-tazobactam as standard care for open pancreatoduodenectomy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03269994.
引用
- D'Angelica MI, Ellis RJ, Liu JB, et al. Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. JAMA. 2023. PMID: 37078771. doi:10.1001/jama.2023.5728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。